Trxade Group (MEDS)
(Delayed Data from NSDQ)
$7.90 USD
+0.21 (2.73%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.94 +0.04 (0.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MEDS 7.90 +0.21(2.73%)
Will MEDS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MEDS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MEDS
Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
MEDS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
Other News for MEDS
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC?s Executive Leadership Team
Trxade Health appoints Mani as President, Hariharan as CEO of Scienture
Trxade Group’s Strategic Merger and Rebranding as Scienture Holdings
Trxade Health acquires Scienture in all-stock transaction valued at $103M
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million